SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001811764-23-000003
Filing Date
2023-02-07
Accepted
2023-02-07 08:00:26
Documents
12
Period of Report
2023-02-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pnt-20230202.htm   iXBRL 8-K 36801
  Complete submission text file 0001811764-23-000003.txt   173109

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pnt-20230202.xsd EX-101.SCH 1917
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pnt-20230202_lab.xml EX-101.LAB 23874
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pnt-20230202_pre.xml EX-101.PRE 12531
6 EXTRACTED XBRL INSTANCE DOCUMENT pnt-20230202_htm.xml XML 11209
Mailing Address 4850 WEST 78TH STREET INDIANAPOLIS IN 46268
Business Address 4850 WEST 78TH STREET INDIANAPOLIS IN 46268 (317) 543-9957
POINT Biopharma Global Inc. (Filer) CIK: 0001811764 (see all company filings)

IRS No.: 850800493 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39373 | Film No.: 23592810
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences